BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Avan A, Narayan R, Giovannetti E, Peters GJ. Role of Akt signaling in resistance to DNA-targeted therapy. World J Clin Oncol 2016; 7(5): 352-369 [PMID: 27777878 DOI: 10.5306/wjco.v7.i5.352] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 27] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Marquard FE, Jücker M. PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer. Biochemical Pharmacology 2020;172:113729. [DOI: 10.1016/j.bcp.2019.113729] [Cited by in Crossref: 48] [Cited by in F6Publishing: 50] [Article Influence: 24.0] [Reference Citation Analysis]
2 Maloney SM, Hoover CA, Morejon-Lasso LV, Prosperi JR. Mechanisms of Taxane Resistance. Cancers (Basel). 2020;12. [PMID: 33182737 DOI: 10.3390/cancers12113323] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
3 Eyermann CE, Haley JD, Alexandrova EM. The HSP-RTK-Akt axis mediates acquired resistance to Ganetespib in HER2-positive breast cancer. Cell Death Dis 2021;12:126. [PMID: 33500390 DOI: 10.1038/s41419-021-03414-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Pathak GP, Shah R, Kennedy BE, Murphy JP, Clements D, Konda P, Giacomantonio M, Xu Z, Schlaepfer IR, Gujar S. RTN4 Knockdown Dysregulates the AKT Pathway, Destabilizes the Cytoskeleton, and Enhances Paclitaxel-Induced Cytotoxicity in Cancers. Mol Ther 2018;26:2019-33. [PMID: 30078441 DOI: 10.1016/j.ymthe.2018.05.026] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
5 Jayaraman S, Hou X, Kuffel MJ, Suman VJ, Hoskin TL, Reinicke KE, Monroe DG, Kalari KR, Tang X, Zeldenrust MA, Cheng J, Bruinsma ES, Buhrow SA, McGovern RM, Safgren SL, Walden CA, Carter JM, Reid JM, Ingle JN, Ames MM, Hawse JR, Goetz MP. Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer. Breast Cancer Res 2020;22:51. [PMID: 32430040 DOI: 10.1186/s13058-020-01286-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
6 Modarres P, Mohamadi Farsani F, Nekouie AA, Vallian S. Meta-analysis of gene signatures and key pathways indicates suppression of JNK pathway as a regulator of chemo-resistance in AML. Sci Rep 2021;11:12485. [PMID: 34127725 DOI: 10.1038/s41598-021-91864-2] [Reference Citation Analysis]
7 van Zweeden AA, Opperman RCM, Honeywell RJ, Peters GJ, Verheul HMW, van der Vliet HJ, Poel D. The prognostic impact of circulating miRNAs in patients with advanced esophagogastric cancer during palliative chemotherapy. Cancer Treat Res Commun 2021;27:100371. [PMID: 33866108 DOI: 10.1016/j.ctarc.2021.100371] [Reference Citation Analysis]
8 Akbari Dilmaghani N, Safaroghli-Azar A, Pourbagheri-Sigaroodi A, Bashash D. The PI3K/Akt/mTORC signaling axis in head and neck squamous cell carcinoma: Possibilities for therapeutic interventions either as single agents or in combination with conventional therapies. IUBMB Life 2021;73:618-42. [PMID: 33476088 DOI: 10.1002/iub.2446] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Götting I, Jendrossek V, Matschke J. A New Twist in Protein Kinase B/Akt Signaling: Role of Altered Cancer Cell Metabolism in Akt-Mediated Therapy Resistance. Int J Mol Sci 2020;21:E8563. [PMID: 33202866 DOI: 10.3390/ijms21228563] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
10 Cuesta C, Arévalo-Alameda C, Castellano E. The Importance of Being PI3K in the RAS Signaling Network. Genes (Basel) 2021;12:1094. [PMID: 34356110 DOI: 10.3390/genes12071094] [Reference Citation Analysis]
11 Zhao Z, Chu W, Zheng Y, Wang C, Yang Y, Xu T, Yang X, Zhang W, Ding X, Li G, Zhang H, Zhou J, Ye J, Wu H, Song X, Wu Y. Cytoplasmic eIF6 promotes OSCC malignant behavior through AKT pathway. Cell Commun Signal 2021;19:121. [PMID: 34922580 DOI: 10.1186/s12964-021-00800-4] [Reference Citation Analysis]
12 Guleria C, Suri V, Kapoor R, Minz RW, Aggarwal R. Human papillomavirus 16 infection alters the Toll-like receptors and downstream signaling cascade: A plausible early event in cervical squamous cell carcinoma development. Gynecol Oncol 2019;155:151-60. [PMID: 31375269 DOI: 10.1016/j.ygyno.2019.07.023] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
13 Yin S, Liu L, Brobbey C, Palanisamy V, Ball LE, Olsen SK, Ostrowski MC, Gan W. PRMT5-mediated arginine methylation activates AKT kinase to govern tumorigenesis. Nat Commun 2021;12:3444. [PMID: 34103528 DOI: 10.1038/s41467-021-23833-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Ghaemimanesh F, Mehravar M, Milani S, Poursani EM, Saliminejad K. The multifaceted role of sortilin/neurotensin receptor 3 in human cancer development. J Cell Physiol 2021;236:6271-81. [PMID: 33634506 DOI: 10.1002/jcp.30344] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Aytatli A, Barlak N, Sanli F, Caglar HO, Gundogdu B, Tatar A, Ittmann M, Karatas OF. AZD4547 targets the FGFR/Akt/SOX2 axis to overcome paclitaxel resistance in head and neck cancer. Cell Oncol (Dordr) 2021. [PMID: 34837170 DOI: 10.1007/s13402-021-00645-6] [Reference Citation Analysis]
16 Tomita K, Fukumoto M, Itoh K, Kuwahara Y, Igarashi K, Nagasawa T, Suzuki M, Kurimasa A, Sato T. MiR-7-5p is a key factor that controls radioresistance via intracellular Fe2+ content in clinically relevant radioresistant cells. Biochem Biophys Res Commun 2019;518:712-8. [PMID: 31472959 DOI: 10.1016/j.bbrc.2019.08.117] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
17 de Mey S, Dufait I, De Ridder M. Radioresistance of Human Cancers: Clinical Implications of Genetic Expression Signatures. Front Oncol 2021;11:761901. [PMID: 34778082 DOI: 10.3389/fonc.2021.761901] [Reference Citation Analysis]
18 Jadhao M, Tsai EM, Yang HC, Chen YF, Liang SS, Wang TN, Teng YN, Huang HW, Wang LF, Chiu CC. The Long-Term DEHP Exposure Confers Multidrug Resistance of Triple-Negative Breast Cancer Cells through ABC Transporters and Intracellular ROS. Antioxidants (Basel) 2021;10:949. [PMID: 34208283 DOI: 10.3390/antiox10060949] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Moselhy J, Suman S, Alghamdi M, Chandarasekharan B, Das TP, Houda A, Ankem M, Damodaran C. Withaferin A Inhibits Prostate Carcinogenesis in a PTEN-deficient Mouse Model of Prostate Cancer. Neoplasia 2017;19:451-9. [PMID: 28494348 DOI: 10.1016/j.neo.2017.04.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
20 Huang H, Yi JK, Lim SG, Park S, Zhang H, Kim E, Jang S, Lee MH, Liu K, Kim KR, Kim EK, Lee Y, Kim SH, Ryoo ZY, Kim MO. Costunolide Induces Apoptosis via the Reactive Oxygen Species and Protein Kinase B Pathway in Oral Cancer Cells. Int J Mol Sci 2021;22:7509. [PMID: 34299129 DOI: 10.3390/ijms22147509] [Reference Citation Analysis]
21 Sobhani N, Roviello G, Corona SP, Scaltriti M, Ianza A, Bortul M, Zanconati F, Generali D. The prognostic value of PI3K mutational status in breast cancer: A meta-analysis. J Cell Biochem. 2018;119:4287-4292. [PMID: 29345357 DOI: 10.1002/jcb.26687] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 7.5] [Reference Citation Analysis]
22 Wijnen R, Pecoraro C, Carbone D, Fiuji H, Avan A, Peters GJ, Giovannetti E, Diana P. Cyclin Dependent Kinase-1 (CDK-1) Inhibition as a Novel Therapeutic Strategy against Pancreatic Ductal Adenocarcinoma (PDAC). Cancers (Basel) 2021;13:4389. [PMID: 34503199 DOI: 10.3390/cancers13174389] [Reference Citation Analysis]
23 Tang Y, Zong S, Zeng H, Ruan X, Yao L, Han S, Hou F. MicroRNAs and angiogenesis: a new era for the management of colorectal cancer. Cancer Cell Int 2021;21:221. [PMID: 33865381 DOI: 10.1186/s12935-021-01920-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Cai S, Cheng X, Liu Y, Lin Z, Zeng W, Yang C, Liu L, Chukwuebuka OA, Li W. EYA1 promotes tumor angiogenesis by activating the PI3K pathway in colorectal cancer. Exp Cell Res 2018;367:37-46. [PMID: 29496520 DOI: 10.1016/j.yexcr.2018.02.028] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
25 Van Den Borg R, Leonetti A, Tiseo M, Giovannetti E, Peters GJ. Novel targeted strategies to overcome resistance in small-cell lung cancer: focus on PARP inhibitors and rovalpituzumab tesirine. Expert Rev Anticancer Ther 2019;19:461-71. [PMID: 31148500 DOI: 10.1080/14737140.2019.1624530] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
26 Bahrami A, Khazaei M, Shahidsales S, Hassanian SM, Hasanzadeh M, Maftouh M, Ferns GA, Avan A. The Therapeutic Potential of PI3K/Akt/mTOR Inhibitors in Breast Cancer: Rational and Progress. J Cell Biochem 2018;119:213-22. [PMID: 28513879 DOI: 10.1002/jcb.26136] [Cited by in Crossref: 41] [Cited by in F6Publishing: 46] [Article Influence: 8.2] [Reference Citation Analysis]
27 Bahrami A, Khazaei M, Hasanzadeh M, ShahidSales S, Joudi Mashhad M, Farazestanian M, Sadeghnia HR, Rezayi M, Maftouh M, Hassanian SM, Avan A. Therapeutic Potential of Targeting PI3K/AKT Pathway in Treatment of Colorectal Cancer: Rational and Progress. J Cell Biochem. 2018;119:2460-2469. [PMID: 28230287 DOI: 10.1002/jcb.25950] [Cited by in Crossref: 53] [Cited by in F6Publishing: 61] [Article Influence: 10.6] [Reference Citation Analysis]
28 Moosavi F, Giovannetti E, Peters GJ, Firuzi O. Combination of HGF/MET-targeting agents and other therapeutic strategies in cancer. Crit Rev Oncol Hematol 2021;160:103234. [PMID: 33497758 DOI: 10.1016/j.critrevonc.2021.103234] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
29 Da Silva CG, Peters GJ, Ossendorp F, Cruz LJ. The potential of multi-compound nanoparticles to bypass drug resistance in cancer. Cancer Chemother Pharmacol 2017;80:881-94. [PMID: 28887666 DOI: 10.1007/s00280-017-3427-1] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
30 Du J, Zhang X, Zhou H, Miao Y, Han Y, Han Q, Wang E. Alex3 suppresses non-small cell lung cancer invasion via AKT/Slug/E-cadherin pathway. Tumour Biol 2017;39:1010428317701441. [PMID: 28705116 DOI: 10.1177/1010428317701441] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
31 Noordhuis P, Laan AC, van de Born K, Honeywell RJ, Peters GJ. Coexisting Molecular Determinants of Acquired Oxaliplatin Resistance in Human Colorectal and Ovarian Cancer Cell Lines. Int J Mol Sci 2019;20:E3619. [PMID: 31344863 DOI: 10.3390/ijms20153619] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]